Frontiers in Oncology (Jan 2025)
Long-term disease control in dedifferentiated liposarcoma: a case report on trabectedin priming followed by PD-1 inhibition
- Johannes M. Waldschmidt,
- Johannes M. Waldschmidt,
- Lukas Haug,
- Lukas Haug,
- Christine Riedhammer,
- Christine Riedhammer,
- Christoph K. W. Deinzer,
- Marcus Zimmermann,
- Marcus Zimmermann,
- Anke Heidemeier,
- Anke Heidemeier,
- Peter Raab,
- Peter Raab,
- Maximilian Rudert,
- Maximilian Rudert,
- Anne Hendricks,
- Anne Hendricks,
- Johan F. Lock,
- Johan F. Lock,
- Viktoria Buck,
- Viktoria Buck,
- Andreas Rosenwald,
- Andreas Rosenwald,
- Hermann Einsele,
- Hermann Einsele,
- Peter Reichardt,
- Volker Kunzmann,
- Volker Kunzmann,
- Armin Wiegering,
- Armin Wiegering,
- Daniel Pink,
- Daniel Pink,
- K. Martin Kortüm,
- K. Martin Kortüm
Affiliations
- Johannes M. Waldschmidt
- Department of Internal Medicine II, University Hospital Würzburg, Würzburg, Germany
- Johannes M. Waldschmidt
- Bavarian Cancer Research Centre (BZKF), Würzburg, Germany
- Lukas Haug
- Bavarian Cancer Research Centre (BZKF), Würzburg, Germany
- Lukas Haug
- Department of Pathology, University Hospital Würzburg, Würzburg, Germany
- Christine Riedhammer
- Department of Internal Medicine II, University Hospital Würzburg, Würzburg, Germany
- Christine Riedhammer
- Bavarian Cancer Research Centre (BZKF), Würzburg, Germany
- Christoph K. W. Deinzer
- Department of Internal Medicine VIII, University Hospital Tübingen, Tübingen, Germany
- Marcus Zimmermann
- Bavarian Cancer Research Centre (BZKF), Würzburg, Germany
- Marcus Zimmermann
- Department of Radiation Therapy, University Hospital Würzburg, Würzburg, Germany
- Anke Heidemeier
- Bavarian Cancer Research Centre (BZKF), Würzburg, Germany
- Anke Heidemeier
- Department of Radiology, University Hospital Würzburg, Würzburg, Germany
- Peter Raab
- Bavarian Cancer Research Centre (BZKF), Würzburg, Germany
- Peter Raab
- Department of Orthopaedic Surgery, König Ludwig Haus, University of Würzburg, Würzburg, Germany
- Maximilian Rudert
- Bavarian Cancer Research Centre (BZKF), Würzburg, Germany
- Maximilian Rudert
- Department of Orthopaedic Surgery, König Ludwig Haus, University of Würzburg, Würzburg, Germany
- Anne Hendricks
- Bavarian Cancer Research Centre (BZKF), Würzburg, Germany
- Anne Hendricks
- Department of Visceral Surgery, University Hospital Würzburg, Würzburg, Germany
- Johan F. Lock
- Bavarian Cancer Research Centre (BZKF), Würzburg, Germany
- Johan F. Lock
- Department of Visceral Surgery, University Hospital Würzburg, Würzburg, Germany
- Viktoria Buck
- Bavarian Cancer Research Centre (BZKF), Würzburg, Germany
- Viktoria Buck
- Department of Pathology, University Hospital Würzburg, Würzburg, Germany
- Andreas Rosenwald
- Bavarian Cancer Research Centre (BZKF), Würzburg, Germany
- Andreas Rosenwald
- Department of Pathology, University Hospital Würzburg, Würzburg, Germany
- Hermann Einsele
- Department of Internal Medicine II, University Hospital Würzburg, Würzburg, Germany
- Hermann Einsele
- Bavarian Cancer Research Centre (BZKF), Würzburg, Germany
- Peter Reichardt
- Department of Oncology, Helios Klinikum Berlin-Buch, Berlin, Germany
- Volker Kunzmann
- Department of Internal Medicine II, University Hospital Würzburg, Würzburg, Germany
- Volker Kunzmann
- Bavarian Cancer Research Centre (BZKF), Würzburg, Germany
- Armin Wiegering
- Bavarian Cancer Research Centre (BZKF), Würzburg, Germany
- Armin Wiegering
- Department of Visceral Surgery, University Hospital Würzburg, Würzburg, Germany
- Daniel Pink
- 0Department of Oncology and Palliative Care, Helios Klinikum Bad Saarow, Bad Saarow, Germany
- Daniel Pink
- 1Klinik und Poliklinik für Innere Medizin C, Universitätsmedizin Greifswald, Greifswald, Germany
- K. Martin Kortüm
- Department of Internal Medicine II, University Hospital Würzburg, Würzburg, Germany
- K. Martin Kortüm
- Bavarian Cancer Research Centre (BZKF), Würzburg, Germany
- DOI
- https://doi.org/10.3389/fonc.2024.1518775
- Journal volume & issue
-
Vol. 14
Abstract
BackgroundDedifferentiated liposarcoma (DDLPS) is a rare mesenchymal cancer originating from the adipose tissue, with poor survival rates for most patients, highlighting the critical need for novel treatment options.Case descriptionThis report examines the efficacy and safety of sequential pre-treatment with the marine-derived alkaloid trabectedin followed by checkpoint inhibition using the anti-PD-1 antibody nivolumab in a 63-year-old male patient with unresectable retroperitoneal DDLPS. Treatment was initiated at the time of the seventh relapse as part of the NitraSarc phase 2 multicenter trial for inoperable soft tissue sarcoma conducted by the German Interdisciplinary Sarcoma Group (GISG-15, NCT03590210). The patient demonstrated an immediate tumor response, and in combination with minor surgery, achieved R0 resection status, which was subsequently maintained without the need for further therapy for the past 52 months. Correlative molecular analyses revealed a sustained DNA damage repair machinery and downregulation of PD-1 protein expression in post-treatment tumor samples.ConclusionThis report provides exemplary insight on the feasibility and efficacy of sequential pre-treatment with trabectedin as a priming strategy for PD-1 inhibition in advanced DDLPS. Full trial results from NitraSarc are pending for publication.
Keywords
